DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).

NCT02035813 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

116

Enrollment

OTHER

Sponsor class

Conditions

HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer
HER2-negative Circulating Tumor Cells
Postmenopausal Female Patients

Interventions

DRUG: Ribociclib
DRUG: Eribulin

Sponsor

Prof. Wolfgang Janni